FATE THERAPEUTICS INC Employee Count
The employee counts FATE THERAPEUTICS INC states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 161; Filing 2026-02-26; Lease expense per employee $113,142.86.
- 2024-12-31: Employees (as filed) 181; Filing 2025-03-05; Lease expense per employee $111,618.78.
- 2023-12-31: Employees (as filed) 181; Filing 2024-02-26; Lease expense per employee $97,563.54.
- 2022-12-31: Employees (as filed) 551; Filing 2023-02-28; Lease expense per employee $36,729.58.
- Available history
- 2018-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 161 full-time | 2026-02-26 | $113,142.86 operating + variable |
| 2024-12-31 | 181 full-time | 2025-03-05 | $111,618.78 operating + variable |
| 2023-12-31 | 181 full-time | 2024-02-26 | $97,563.54 operating + variable |
| 2022-12-31 | 551 full-time | 2023-02-28 | $36,729.58 operating + variable + short-term |
| 2021-12-31 | 449 full-time | 2022-02-28 | $41,590.20 operating + variable + short-term |
| 2020-12-31 | 279 full-time | 2021-02-24 | $63,677.42 operating + variable + short-term |
| 2019-12-31 | 178 full-time | 2020-03-02 | $53,601.12 operating + variable + short-term |
| 2018-12-31 | 104 full-time | 2019-03-05 | $22,115.38 lease and rental expense |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |